Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of first-line osimertinib plus locally ablative radiotherapy for synchronous oligometastatic EGFR-mutant NSCLC
NL-OMON54434Phase 2Withdrawn
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Primary endpoints: Proportion of patients with grade >=2 pneumonitis requiring medical treatment and Progression-free survival. Planned start Mar 2023; status: withdrawn.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54434.